

LITERATURA

- Pilkova A, Hartinger MJ. Změny farmakokinetiky lecv u obezích pacientů. *Vnitř Lék.* 2020;66:465-471.
- Rocca B, Fox KAA, Ajjan RA, et al. Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. *Eur Heart J.* 2018;39:1672-1686f. DOI: 10.1093/eurheartj/ehy066.
- Liu J, Qiao X, Wu M, et al. Strategies involving low-molecular-weight heparin for the treatment and prevention of venous thromboembolism in patients with obesity: A systematic review and meta-analysis. *Front Endocrinol (Lausanne).* 2023;14:1084511. DOI: 10.3389/fendo.2023.1084511.
- Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. *Eur Heart J.* 2021;42:373-498. DOI: 10.1093/eurheartj/ehaa612.
- Freeman AL, Pendleton RC, Rondina MT. Prevention of venous thromboembolism in obesity. *Expert Rev Cardiovasc Ther.* 2010;8:1711-1721. DOI: 10.1586/erc.10.160.
- Lexicomp Online. In: Waltham, MA: UpToDate, Inc.; přístup 12/2023.
- IBM Micromedex. In: Greenwood Village (CO): IBM Corporation; přístup 12/2023.
- Fraisse F, Holzapfel L, Couland JM, et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. *Am J Respir Crit Care Med.* 2000;161:1109-1114. DOI: 10.1164/ajrccm.161.4.9807025.
- Platná SPC. Dostupná z Databáze léků, www.sukl.cz. In: Státní ústav pro kontrolu léčiv; přístup 12/2023.
- Kalfarentzos F, Stavropoulou F, Yarmenitis S, et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. *Obes Surg.* 2001;11:670-676. DOI: 10.1381/09608920160558588.
- Vavken P, Lunzer A, Grohs JG. A prospective cohort study on the effectiveness of 3500 IU versus 5000 IU bemiparin in the prophylaxis of postoperative thrombotic events in obese patients undergoing orthopedic surgery. *Wien Klin Wochenschr.* 2009;121:454-458. DOI: 10.1007/s00508-009-1175-x.
- Vandiver JW, Ritz LJ, Lalama JT. Chemical prophylaxis to prevent venous thromboembolism in morbid obesity: literature review and dosing recommendations. *J Thromb Thrombolysis.* 2016;41:475-481. DOI: 10.1007/s11239-015-1231-5.
- Soyombo BM, Taylor A, Gillard C, et al. Impact of body mass index on 90-day warfarin requirements: a retrospective chart review. *Ther Adv Cardiovasc Dis.* 2021;15:17539447211012803. DOI: 10.1177/17539447211012803.
- Stevens SM, Woller SC, Baumann Kreuziger L, et al. Executive Summary: Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. *Chest.* 2021;160:2247-2259. DOI: 10.1016/j.chest.2021.07.056.
- Mocini D, Di Fusco SA, Mocini E, et al. Direct Oral Anticoagulants in Patients with Obesity and Atrial Fibrillation: Position Paper of Italian National Association of Hospital Cardiologists (ANMCO). *J Clin Med.* 2021;10. DOI: 10.3390/jcm10184185.
- Martin K, Beyer-Westendorf J, Davidson BL, et al. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. *J Thromb Haemost.* 2016;14:1308-1313. DOI: 10.1111/jth.13323.
- Martin KA, Beyer-Westendorf J, Davidson BL, et al. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. *J Thromb Haemost.* 2021;19:1874-1882. DOI: 10.1111/jth.15358.
- Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. *EP Europace.* 2021;23:1612-1676. DOI: 10.1093/europace/euab065.
- Thangjui S, Kewcharoen J, Yodsuan R, et al. Efficacy and safety of direct oral anticoagulant in morbidly obese patients with atrial fibrillation: systematic review and meta-analysis. *Eur Heart J Cardiovasc Pharmacother.* 2022;8:325-335. DOI: 10.1093/ehjcvp/pvab026.
- Deitelzweig S, Keshishian A, Kang A, et al. Effectiveness and Safety of Oral Anticoagulants among NVAf Patients with Obesity: Insights from the ARISTOPHANES Study. *J Clin Med.* 2020;9. DOI: 10.3390/jcm9061633.
- Leong R, Chu DK, Crowther MA, et al. Direct oral anticoagulants after bariatric surgery-What is the evidence? *J Thromb Haemost.* 2022;20:1988-2000. DOI: 10.1111/jth.15823.
- Pilková A, Hartinger JM. Změny farmakokinetiky pacientů s obezitou. In: Fábryová a kol. *Klinická obezitologie. 2. vydání, Brno: Facta Medica; 2023.*
- Martin KA, Lee CR, Farrell TM, et al. Oral Anticoagulant Use After Bariatric Surgery: A Literature Review and Clinical Guidance. *Am J Med.* 2017;130:517-524. DOI: 10.1016/j.amjmed.2016.12.033.

Připravujeme do Vnitřního lékařství

2024

2

- Hlavní téma: Metabolický syndrom
- Osteoporóza u dospělých v klinické praxi (2): Terapie
- Novinky v patofyziologii a léčbě hypertrofické kardiomyopatie
- Prevence rozvoje pokročilého CHSS – možnosti farmakoterapie
- Aktuální trendy v léčbě rezistentní hypertenze
- Co je nového v geriatрии
- ... a mnoho dalšího



VYJDE
V DUBNU